BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer

And in later-line patients, the results look genuinely impressive. Among patients who'd already tried and failed a KRAS G12C inhibitor, BBO-8520 combined with pembrolizumab (Merck's blockbuster immunotherapy) produced a 75% response rate at the 500 mg dose. Across all dose levels, that number was 53% in 17 patients. In KRAS G12C inhibitor-naïve later-line patients receiving BBO-8520 alone, the response rate hit 63% with 100% disease control and no serious liver toxicity.

Those are strong numbers for a tough-to-treat population. The problem is that the first-line data was paper-thin: only three patients had been treated in the front-line combination cohort. All three responded, but three patients isn't a dataset; it's an anecdote. BridgeBio apparently saw enough uncertainty in the first-line path to pivot its resources elsewhere.

A Crowded Room Just Got More Awkward

BridgeBio's retreat is especially notable because the KRAS G12C space is already packed like a Tokyo subway car at rush hour.

Sotorasib and adagrasib are the established players, joined by at least four approved Chinese competitors (fulzerasib, garsorasib, glecirasib, and sosimerasib). Behind them, Roche's divarasib, Eli Lilly's olomorasib, and Revolution Medicines' elironrasib are all pushing through clinical development.

The real action in 2026 is happening in first-line combinations with checkpoint inhibitors. Merck and Lilly have both secured Breakthrough Therapy designations for their first-line KRAS programs and are running Phase 3 trials. BridgeBio was supposed to be part of that race. Now it's sitting on the sidelines, watching competitors chase the prize it just gave up.

Meanwhile, the strategic frontier is shifting toward KRAS G12D, a different mutation that's especially important in pancreatic and colorectal cancers. Among the handful of drugs in clinical development for KRAS G12D, GenFleet's GFH-375 is leading in Phase 2. BridgeBio says it's redirecting resources toward its own next-generation assets, BBO-11818 and BBO-10203, for KRAS-mutant cancers, but those programs are earlier and unproven.

What the Analysts Are Saying (and Not Saying)

The analyst reaction was a study in diplomatic optimism. Nobody outright downgraded the stock, but the price target cuts told the real story.

Leerink Partners slashed its target from $39 to $27 while maintaining an Outperform rating. Stifel went from $23 to $15 but kept its Buy. Raymond James trimmed from $24 to $22. The consensus remains heavily skewed toward Buy ratings, which sounds encouraging until you remember the stock is trading at $5.52. Even the most bullish target implies the stock needs to nearly 5x from here.

The polite framing from analysts is that this was a "pipeline reprioritization." The less polite interpretation is that BridgeBio looked at its first-line data (or lack thereof), looked at the competitive landscape, and blinked.

The Bigger Lesson

BridgeBio Oncology's story is a cautionary tale about the difference between a drug that works and a drug that wins. BBO-8520 clearly has activity in later-line KRAS G12C lung cancer, and a 75% response rate in inhibitor-experienced patients is nothing to sneeze at.

But biotech valuations aren't built on later-line niches. They're built on the promise of becoming a first-line standard of care, which is where the patient volume, the pricing power, and the peak sales projections live. When you voluntarily shrink from a larger patient opportunity to a smaller one, the stock price adjusts accordingly.

The KRAS G12C space is entering its "combination era," where the winners will be drugs that pair well with immunotherapy and can hold up in first-line randomized trials against the current standard. BridgeBio just admitted it might not have that drug. Whether its next-generation assets (BBO-11818, BBO-10203) can fill the gap remains to be seen, but investors clearly aren't willing to wait on faith alone.

Sometimes the smartest strategic move still feels like a loss. This is one of those times.

Novartis Just Had Its Worst Month in Years. Now Shareholders Want Heads to Roll.

A major Novartis shareholder is demanding a board overhaul after back-to-back trial failures and a record stock drop. When your $12 billion acquisition produces a drug that flunks its biggest test, someone has to answer for it.